Publication Cover
Natural Product Research
Formerly Natural Product Letters
Volume 38, 2024 - Issue 5
133
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

Rosmarinus officinalis essential oils’ eradication of beta-lactamase and multidrug resistant clinical bacterial pathogens from hospital settings

, , , , &
Pages 796-806 | Received 13 Jan 2023, Accepted 04 Apr 2023, Published online: 19 Apr 2023
 

Abstract

Antibiotics have become increasingly ineffective in the face of bacterial resistance, particularly in hospitals. Interestingly, there is high demand for bioprospecting of secondary metabolites, particularly for treating multidrug-resistant clinical diseases. In fact, Rosemary has been used for its antiseptic properties dating back to antiquity. The aim of this research is to evaluate the effectiveness of Rosmarinus officinalis essential oil against multidrug-resistant clinical bacterial pathogens. Results showed promising antibacterial activity against seven bacteria: Escherichia coli, Enterobacter cloacae, Staphylococcus aureus, Serratia odorifera, Klebsiella pneumoniae, Klebsiella oxytoca, Aeromonas hydrophila with MIC values of 35.7, 17.85, 71.4, 8.9, 17.8, 285.7, 35.7 µg/ml respectively and MBC values of 142.8, 71.4, 285.7, 35.7, 71.4, 571.5,71.4 µg/ml respectively. This study suggests that Rosmarinus essential oil can be used as a therapeutic agent in the fight against a wide range of multi-resistant bacteria.

Graphical Abstract

Acknowledgements

We would like to express our gratitude to the entire personnel of the Akid Lotfi central laboratory at the Laghouat hospital for their invaluable assistance in collecting reagents and operating various types of equipment.

Disclosure statement

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.